{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:37Z","timestamp":1794047497686,"version":"4.8.0"},"reference-count":33,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Infections are an important cause of morbidity and mortality in patients with lower-risk myelodysplastic syndromes (LR-MDS). Studies regarding risk factors for infections are, however, limited in this population. This study aimed to investigate the prevalence and risk factors for infections and infection-related death in patients with LR-MDS. The study included 2,552 patients from the European MDS (EUMDS) Registry, which prospectively collects observational data on newly diagnosed MDS patients from 17 countries. The prevalence of infections and infection-related death was determined. Risk factors for infections and infection-related death occurring within 1 year from diagnosis were analyzed in separate multivariable logistic regression models. A third model that only included LR-MDS patients who experienced an infectious episode within the first year after diagnosis was used to analyze risk factors associated with infection-related death in patients with an infectious episode. The prevalence of infections was 7.6%, and 24.6% of all deaths were due to infections. In multivariable analysis, an independent association with increased risk for infections was found for hemoglobin level &lt;8 g\/dL, platelet count &lt;50x109\/L, absolute neutrophil count &lt;0.8x109\/L, intermediate\/poor\/very poor cytogenetics, and having received red blood cell transfusions at baseline. An independent association with increased risk of infection-related death was found for older age at diagnosis, hemoglobin level &lt;8 g\/dL, and platelet count &lt;50x109\/L. Patients with an increased risk of infections could benefit from close monitoring, especially in the first months after diagnosis. Future research should focus on the causality and severity of infections and risk factors over time, to provide more guidance for monitoring.<\/jats:p>","DOI":"10.3324\/haematol.2024.286880","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T05:14:48Z","timestamp":1744262088000},"page":"2367-2375","source":"Crossref","is-referenced-by-count":5,"title":["Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry"],"prefix":"10.3324","volume":"110","author":[{"given":"Bente","family":"Houtman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"Van Marrewijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argiris","family":"Symeonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Mittelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Stauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"\u010cerm\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hellstr\u00f6m-Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Comont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Culligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kotsianidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"De Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Langemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlijn","family":"Hoeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EUMDS","family":"Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"80204","doi-asserted-by":"crossref","unstructured":"Malcovati L, Hellstr\u00f6m-Lindberg E, Bowen D. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122(17):2943-2964.","DOI":"10.1182\/blood-2013-03-492884"},{"key":"80205","doi-asserted-by":"crossref","unstructured":"Greenberg P, Cox C, LeBeau MM. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-2088.","DOI":"10.1182\/blood.V89.6.2079"},{"key":"80206","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Tuechler H, Schanz J. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012; 120(12):2454-2465.","DOI":"10.1182\/blood-2012-03-420489"},{"key":"80207","doi-asserted-by":"crossref","unstructured":"Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA. 2022; 328(9):872-880.","DOI":"10.1001\/jama.2022.14578"},{"key":"80208","doi-asserted-by":"crossref","unstructured":"Carraway HE, Saygin C. Therapy for lower-risk MDS. Hematology Am Soc Hematol Educ Program. 2020; 2020(1):426-433.","DOI":"10.1182\/hematology.2020000127"},{"key":"80209","doi-asserted-by":"crossref","unstructured":"Dayyani F, Conley AP, Strom SS. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010; 116(9):2174-2179.","DOI":"10.1002\/cncr.24984"},{"key":"80210","doi-asserted-by":"crossref","unstructured":"M\u0105dry K, Lis K, Fenaux P. Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): a report from the European MDS Registry. Br J Haematol. 2023; 200(4):451-461.","DOI":"10.1111\/bjh.18542"},{"key":"80211","doi-asserted-by":"crossref","unstructured":"Nachtkamp K, Stark R, Strupp C. Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol. 2016; 95(6):937-944.","DOI":"10.1007\/s00277-016-2649-3"},{"key":"80212","doi-asserted-by":"crossref","unstructured":"Kasprzak A, Andresen J, Nachtkamp K. Infectious complications in patients with myelodysplastic syndromes: a report from the D\u00fcsseldorf MDS Registry. Cancers (Basel). 2024; 16(4):808.","DOI":"10.3390\/cancers16040808"},{"key":"80213","doi-asserted-by":"crossref","unstructured":"Ontiveros-Austria J, Rodriguez-Rodriguez S, Demichelis R, Gonz\u00e1lez Lara MF, Apodaca Chavez EI. Risk factors associated to severe episodes of infection in myelodysplastic syndromes. Blood. 2023; 142(Supplement 1):6493.","DOI":"10.1182\/blood-2023-179673"},{"key":"80214","doi-asserted-by":"crossref","unstructured":"Toma A, Fenaux P, Dreyfus F, Cordonnier C. Infections in myelodysplastic syndromes. Haematologica. 2012; 97(10):1459-1470.","DOI":"10.3324\/haematol.2012.063420"},{"key":"80215","doi-asserted-by":"crossref","unstructured":"Kouroukli O, Symeonidis A, Foukas P, Maragkou MK, Kourea EP. Bone marrow immune microenvironment in myelodysplastic syndromes. Cancers (Basel). 2022; 14(22):5656.","DOI":"10.3390\/cancers14225656"},{"key":"80216","doi-asserted-by":"crossref","unstructured":"Topping J, Taylor A, Nadat F. Inflammatory profile of lower risk myelodysplastic syndromes. Br J Haematol. 2024; 205(3):1044-1054.","DOI":"10.1111\/bjh.19530"},{"key":"80217","doi-asserted-by":"crossref","unstructured":"Merkel D, Filanovsky K, Gafter-Gvili A. Predicting infections in high-risk patients with myelodysplastic syndrome\/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol. 2013; 88(2):130-134.","DOI":"10.1002\/ajh.23368"},{"key":"80218","doi-asserted-by":"crossref","unstructured":"Sullivan LR, Sekeres MA, Shrestha NK. Epidemiology and risk factors for infections in myelodysplastic syndromes. Transpl Infect Dis. 2013; 15(6):652-657.","DOI":"10.1111\/tid.12130"},{"key":"80219","doi-asserted-by":"crossref","unstructured":"Leone G, Pagano L. Infections in myelodysplastic syndrome in relation to stage and therapy. Mediterr J Hematol Infect Dis. 2018; 10(1):e2018039.","DOI":"10.4084\/mjhid.2018.039"},{"key":"80220","doi-asserted-by":"crossref","unstructured":"Ofran Y, Filanovsky K, Gafter-Gvili A. Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2015; 15(6):e95-99.","DOI":"10.1016\/j.clml.2015.02.030"},{"key":"80221","doi-asserted-by":"crossref","unstructured":"de Swart L, Smith A, Johnston TW. Validation of the Revised International Prognostic Scoring System (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) Registry. Br J Haematol. 2015; 170(3):372-383.","DOI":"10.1111\/bjh.13450"},{"key":"80222","doi-asserted-by":"crossref","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-2302.","DOI":"10.1182\/blood-2002-04-1199"},{"key":"80223","doi-asserted-by":"crossref","unstructured":"Pomeroy C, Oken MM, Rydell RE, Filice GA. Infection in the myelodysplastic syndromes. Am J Med. 1991; 90(3):338-344.","DOI":"10.1016\/0002-9343(91)80014-D"},{"key":"80224","doi-asserted-by":"crossref","unstructured":"Sebert M, Aguilar C, Chevret S, Ades L, Lortholary O, Fenaux P. Prognostic factors of infections and effect of primary anti-infectious prophylaxis in MDS patients treated with azacitidine (AZA): a prospective study. Blood. 2014; 124(21):1917.","DOI":"10.1182\/blood.V124.21.1917.1917"},{"key":"80225","doi-asserted-by":"crossref","unstructured":"Cunningham I, MacCallum SJ, Nicholls MD. The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol. 1995; 90(3):602-606.","DOI":"10.1111\/j.1365-2141.1995.tb05590.x"},{"key":"80226","doi-asserted-by":"crossref","unstructured":"Sullivan LR, Sekeres MA, Shrestha NK. Epidemiology and risk factors for infections in myelodysplastic syndromes. Transpl Infect Dis. 2013; 15(6):652-657.","DOI":"10.1111\/tid.12130"},{"key":"80227","doi-asserted-by":"crossref","unstructured":"Ludwig N, Hilger A, Zarbock A, Rossaint J. Platelets at the crossroads of pro-inflammatory and resolution pathways during inflammation. Cells. 2022; 11(12):1957.","DOI":"10.3390\/cells11121957"},{"key":"80228","doi-asserted-by":"crossref","unstructured":"Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection. Semin Thromb Hemost. 2020; 46(3):302-319.","DOI":"10.1055\/s-0040-1708827"},{"key":"80229","doi-asserted-by":"crossref","unstructured":"Gasc\u00f3n P, Zoumbos NC, Young NS. Immunologic abnormalities in patients receiving multiple blood transfusions. Ann Intern Med. 1984; 100(2):173-177.","DOI":"10.7326\/0003-4819-100-2-173"},{"key":"80230","doi-asserted-by":"crossref","unstructured":"Matsagos S, Verigou E, Kourakli A. High frequency of post-transfusion microchimerism among multi-transfused beta-thalassemic patients. Front Med (Lausanne). 2022; 9:845490.","DOI":"10.3389\/fmed.2022.845490"},{"key":"80231","doi-asserted-by":"crossref","unstructured":"Smith BD, Mahmoud D, Dacosta-Byfield S, Rosen VM. Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with\/without transfusions, and with\/without active therapy. Leuk Lymphoma. 2014; 55(5):1119-1125.","DOI":"10.3109\/10428194.2013.820286"},{"key":"80232","doi-asserted-by":"crossref","unstructured":"Sakatoku K, Takeoka Y, Miura A. Combination of frailty status and comorbidity score improves the stratification of survival in patients with myelodysplastic syndrome owing to good predictive capability for infection-related mortality. Clin Lymphoma Myeloma Leuk. 2019; 19(12):799-805.","DOI":"10.1016\/j.clml.2019.09.610"},{"key":"80233","doi-asserted-by":"crossref","unstructured":"Saeed L, Patnaik MM, Begna KH. Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. Blood Cancer J. 2017; 7(3):e550.","DOI":"10.1038\/bcj.2017.30"},{"key":"80234","doi-asserted-by":"crossref","unstructured":"Symeonidis A, Kourakli A, Katevas P. Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur J Haematol. 1991; 47(4):277-281.","DOI":"10.1111\/j.1600-0609.1991.tb01571.x"},{"key":"80235","doi-asserted-by":"crossref","unstructured":"Cordonnier C, Maschmeyer G, Cesaro S, Ljungman P. Reporting infectious complications in haematology clinical trials should be improved. Clin Microbiol Infect. 2019; 25(12):1451-1453.","DOI":"10.1016\/j.cmi.2019.07.024"},{"key":"80236","doi-asserted-by":"crossref","unstructured":"Tau N, Shargian-Alon L, Reich S. Reporting infections in clinical trials of patients with haematological malignancies. Clin Microbiol Infect. 2019; 25(12):1494-1500.","DOI":"10.1016\/j.cmi.2019.04.029"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12019\/78278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12019\/78874","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12019\/78278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:33Z","timestamp":1794046113000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286880","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}